UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study

Voevodskaya, O; Poulakis, K; Sundgren, P; van Westen, D; Palmqvist, S; Wahlund, L-O; Stomrud, E; ... Zetterberg, H; + view all (2019) Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. Neurology , 92 (5) E395-E405. 10.1212/WNL.0000000000006852. Green open access

[thumbnail of Zetterberg VoR e395.full.pdf]
Preview
Text
Zetterberg VoR e395.full.pdf - Published Version

Download (659kB) | Preview

Abstract

Objective To investigate the association between longitudinal changes in proton magnetic resonance spectroscopy (MRS) metabolites and amyloid pathology in individuals without dementia, and to explore the relationship between MRS and cognitive decline. Methods In this longitudinal multiple time point study (a subset of the Swedish BioFINDER), we included cognitively healthy participants, individuals with subjective cognitive decline, and individuals with mild cognitive impairment. MRS was acquired serially in 294 participants (670 individual spectra) from the posterior cingulate/precuneus. Using mixed-effects models, we assessed the association between MRS and baseline β-amyloid (Aβ), and between MRS and the longitudinal Mini-Mental State Examination, accounting for APOE, age, and sex. Results While baseline MRS metabolites were similar in Aβ positive (Aβ+) and negative (Aβ−) individuals, in the Aβ+ group, the estimated rate of change was +1.9%/y for myo-inositol (mI)/creatine (Cr) and −2.0%/y for N-acetylaspartate (NAA)/mI. In the Aβ− group, mI/Cr and NAA/mI yearly change was −0.05% and +1.2%; however, this was not significant across time points. The mild cognitive impairment Aβ+ group showed the steepest MRS changes, with an estimated rate of +2.93%/y (p = 0.07) for mI/Cr and −3.55%/y (p < 0.01) for NAA/mI. Furthermore, in the entire cohort, we found that Aβ+ individuals with low baseline NAA/mI had a significantly higher rate of cognitive decline than Aβ+ individuals with high baseline NAA/mI. Conclusion We demonstrate that the longitudinal change in mI/Cr and NAA/mI is associated with underlying amyloid pathology. MRS may be a useful noninvasive marker of Aβ-related processes over time. In addition, we show that in Aβ+ individuals, baseline NAA/mI may predict the rate of future cognitive decline.

Type: Article
Title: Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study
Open access status: An open access version is available from UCL Discovery
DOI: 10.1212/WNL.0000000000006852
Publisher version: https://doi.org/10.1212/WNL.0000000000006852
Language: English
Additional information: This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited https://creativecommons.org/licenses/by/4.0/
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10072862
Downloads since deposit
58Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item